Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain 'Firmness' test may spot Alzheimer's early

NCT ID NCT06029114

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

Researchers at Mayo Clinic are testing whether measuring brain stiffness with a special MRI scan (magnetic resonance elastography) can serve as a new biomarker for Alzheimer's disease. The study will enroll 450 adults, including healthy volunteers, people with mild cognitive impairment, and those with Alzheimer's. Participants undergo a brain scan that measures tissue stiffness, which may change with disease progression.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Magnetic Resonance Elastography (MRE) scan
What this could lead to
If successful, this could lead to a new, non-invasive way to detect Alzheimer's disease earlier using a simple MRI-based scan.
What could go wrong
This is an observational study, not a treatment trial. Brain stiffness may not prove to be a reliable or practical biomarker for routine diagnosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 450 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2023

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Subjects will be selected from Mayo Alzheimer's Disease Research Center.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for Control Subjects: * In good general health * No Active neurological or psychiatric conditions, if a prior neurological or psychiatric condition was present they must have returned to normal * No cognitive complaints * Normal neurological examination * No psychoactive medications * They may have a chronic medical condition that does not affect cognition * Low Aβ load Pittsburgh compound-B (PiB) ratio \<1.5 Inclusion Criteria for Mild Cognitive Impairment Subjects: * In good general health * Memory complaint documented by the patient and collateral source * Normal general cognitive function as determined by measure of general intellectual function and screening including the Short Test of Mental Status * Normal activities of daily living as documented by history and Record of Independent Living * Not demented by DSM-III-R criteria * Do have an objective memory impairment determined by the clinical judgement of the neuropsychologists and neurologists * High Aβ load Pittsburgh compound-B (PiB) ratio ≥1.5 Inclusion Criteria for Alzheimer's Disease Subjects: * In good general health * Dementia not a result of other medical or psychiatric conditions * Diagnosis of dementia made according to DSM-III-R criteria * Do have objective memory impairment determined by the clinical judgement of the neuropsychologists and neurologists * High Aβ load Pittsburgh compound-B (PiB) ratio ≥1.5 Exclusion Criteria: * Alzheimer's disease or mild cognitive impairment due to a known genetic mutation * Major depression * History of primary or metastatic intracranial neoplasm, significant head trauma, intra-cerebral hemorrhage, hemispheric stroke * Contradictions to MRI imaging including but not limited to cardiac pacemakers, intraocular or intracranial metal, or other MRI incompatible devices. * Pregnant women. Women of child bearing potential will be given a urine pregnancy test prior the MRI scan. Results will be shared with the participant. If the pregnancy test is positive, the participant will not be included within the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Mayo Clinic Minnesota

    Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.